mike.hammerton@pharmaphorum.com, Author at

Deep Dive/ Market Access/ Views & Analysis

ICSs: improving patient and market access at a local level

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Dr Paul Tunnah, IQVIA, Jim McArdle, market access, Matthias Winker, Steven Ferguson, Uday Bose 0 Comment

Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more

ICSs: improving patient and market access at a local level

https://pharmaphorum.com/market-access-2/icss-improving-patient-and-market-access-at-a-local-level/

Market Access/ Views & Analysis/ Views and analysis

Six months after authorization, what do we know about Paxlovid?

mike.hammerton@pharmaphorum.com COVID-19, fda, Paxlovid, Pfizer 0 Comment

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment

Six months after authorization, what do we know about Paxlovid?

https://pharmaphorum.com/market-access-2/six-months-after-authorization-what-do-we-know-about-paxlovid/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Time is motor neurons – the importance of newborn screening in SMA

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, market access, Mike Fraser, Novartis Gene Therapies, spinal muscular atrophy 0 Comment

Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1

Time is motor neurons – the importance of newborn screening in SMA

https://pharmaphorum.com/market-access-2/time-is-motor-neurons-the-importance-of-newborn-screening-in-sma/

Digital/ Views & Analysis/ Views and analysis

How digital is transforming the commercial leader’s role in biopharma

mike.hammerton@pharmaphorum.com biopharma, BrightInsight, digital revolution, Digital transformation 0 Comment

Pharma’s evolving role in patient care The digital revolution has already reshaped the commercial engine of biopharma companies.

How digital is transforming the commercial leader’s role in biopharma

https://pharmaphorum.com/views-and-analysis/digital-transforming-commercial-leaders-role-biopharma/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Is it time to rethink electronic prescribing in the US?

mike.hammerton@pharmaphorum.com Bob Katter, Deep Dive, Deep Dive: Market Access, market access 0 Comment

It is a fact of life that most – if not all – patients will require some form

Is it time to rethink electronic prescribing in the US?

https://pharmaphorum.com/market-access-2/time-to-rethink-electronic-prescribing-us/

R&D/ Views & Analysis/ Views and analysis

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

mike.hammerton@pharmaphorum.com AMR, anti microbial resistance, antibacterial resistance, Micreos Pharmaceuticals, MRSA 0 Comment

Antimicrobial resistance (AMR) is an issue of global concern, killing roughly 1.2 million1 people per year and projected

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

https://pharmaphorum.com/r-d/views-analysis-r-d/combating-antimicrobial-resistance-viable-alternative-traditional-antibiotics/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Combination pricing: access to the future of oncology treatment relies on collaboration

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, market access, Oncology, Sanofi 0 Comment

Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the

Combination pricing: access to the future of oncology treatment relies on collaboration

https://pharmaphorum.com/market-access-2/combination-pricing-access-future-oncology-treatment-relies-collaboration/

Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

Redefining the approach to cancer care – a mission to improve patient outcomes

mike.hammerton@pharmaphorum.com breast cancer, cancer care, company profile, Exact Sciences, her2 0 Comment

Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million

Redefining the approach to cancer care – a mission to improve patient outcomes

https://pharmaphorum.com/oncology/redefining-the-approach-to-cancer-care-a-mission-to-improve-patient-outcomes/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Closing the digital expectation gap in pharma

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Jan Deman, market access, Takeda 0 Comment

Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to

Closing the digital expectation gap in pharma

https://pharmaphorum.com/market-access-2/closing-the-digital-expectation-gap-in-pharma/

Trending

About Mike Hammerton

Posts by Mike Hammerton:

ICSs: improving patient and market access at a local level

Six months after authorization, what do we know about Paxlovid?

Time is motor neurons – the importance of newborn screening in SMA

How digital is transforming the commercial leader’s role in biopharma

Is it time to rethink electronic prescribing in the US?

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

Combination pricing: access to the future of oncology treatment relies on collaboration

Redefining the approach to cancer care – a mission to improve patient outcomes

Closing the digital expectation gap in pharma

Trending

About Mike Hammerton

Posts by Mike Hammerton:

Login